category,datetime,headline,id,image,related,source,summary,url
company,1768262318,Vertex Pharmaceuticals Incorporated (VRTX) 44th Annual J.P. Morgan Healthcare Conference Presentation,138080359,https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png,VRTX,SeekingAlpha,2026-01-12. The following slide deck was published by Vertex Pharmaceuticals Incorporated in conjunction with this event.,https://finnhub.io/api/news?id=9f21927ccab24a0d1d49e28ef1ccf2738a51bf2b02beb9293907fb03ec02016d
company,1768261557,Vertex Pharmaceuticals Incorporated (VRTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript,138080295,https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png,VRTX,SeekingAlpha,Vertex Pharmaceuticals Incorporated (VRTX) 44th Annual J.P.,https://finnhub.io/api/news?id=8904d328fe2e3ee713555a22ef72c4bd3618de6000e3cf8d1a6eea73991e53f0
company,1768237805,Will Vertex (VRTX) Beat Estimates Again in Its Next Earnings Report?,138078139,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,VRTX,Yahoo,Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.,https://finnhub.io/api/news?id=2eb03902a87b01b2e87e53d6e119582df46e6c92ab7551def963e78c02fa8d65
company,1768226734,Here’s What Lifted Vertex Pharmaceuticals (VRTX) in Q4,138072411,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,VRTX,Yahoo,"ClearBridge Investments, an investment management company, released its “ClearBridge Growth Strategy” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. US equities reported a strong but volatile performance in the fourth quarter, with the S&P 500 Index returning 2.7% while the benchmark Russell Midcap Growth Index declined 3.7%. In this environment, a […]",https://finnhub.io/api/news?id=d3d7566a84a5fd042463b4226e4a44334129dd35a700d426c782cceef94ae84b
company,1768217040,AbbVie buys into PD-1/VEGF sweepstakes; Alnylam and Vertex set expectations,138075441,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,VRTX,Yahoo,"AbbVie is paying $650 million for a dual-targeting immunotherapy from China’s RemeGen. Elsewhere, Alnylam missed an earnings target and the FDA flipped its position on a cell therapy from Atara.",https://finnhub.io/api/news?id=4c5cd43b9789dda93c2e7019c0a76364351620a7132db313a44e9fefec4c074b
